AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PARADIGM BIOPHARMACEUTICALS

0.475

+0.000

Volume:859.45K

Turnover:410.47K

Market Cap:184.98M

PE:-10.46

High:0.492

Open:0.470

Low:0.460

Close:0.475

Loading ...

Overview Company News Filings

Paradigm Biopharmaceuticals Ltd - Placement to Fund Global Phase 3 Clinical Trial Setup and Other Strategic Initiatives

THOMSON REUTERS

Paradigm Biopharmaceuticals - a$16M Placement at a$0.40 per Share

THOMSON REUTERS

These small cap ASX shares could surge 27% to 38% higher

This ASX healthcare stock is up 160% in a month! Here's why it's just entered a trading halt

BRIEF-Paradigm Biopharmaceuticals Seeks Trading Halt

Paradigm Biopharmaceuticals Ltd - Trading Halt Pending Capital Raising Announcement

THOMSON REUTERS

PhosCo runs hard on Tunisian phosphate

The West Australian

Paradigm Biopharmaceuticals to Advance Knee Osteoarthritis Trial to Phase 3 Following US FDA Review

MT Newswires Live

Why did this ASX biotech stock explode 52% higher on Monday?

Catalyst Watch: Robotaxi IPO, OPEC+, holiday shopping data, and movie blockbusters

PAR Technology to Exchange $100 Million Convertible Senior Notes Due 2026 for Common Shares

MT Newswires Live

ASX Market Close: Gold hits record high ahead of US election | October 31, 2024

The Market Herald

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

ASX Market Close: Index hits new intra-day high in flat days trade | September 18, 2024

The Market Herald

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

The Market Herald

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/PAR.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PAR.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","market":"AU","secType":"STK","nameCN":"PARADIGM BIOPHARMACEUTICALS","latestPrice":0.475,"timestamp":1741583520000,"preClose":0.475,"halted":0,"volume":859452,"delay":0,"changeRate":0,"change":0,"floatShares":345063689,"shares":389428603,"eps":-0.045402,"lyrEps":-0.15999,"pbRate":5.43,"amount":410468,"amplitude":0.067368,"volumeRatio":0.718576,"dividePrice":0,"prevYearClose":0.3,"fiveDayClose":0.495,"twentyDayClose":0.54},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","floatShares":345063689,"roa":"-33.14%","roe":"-42.91%","lyrEps":-0.15999,"volumeRatio":0.718576,"shares":389428603,"dividePrice":0,"high":0.492,"amplitude":0.067368,"preClose":0.475,"low":0.46,"week52Low":0.132,"pbRate":"5.43","psRate":"11076.56","week52High":0.66,"institutionHeld":0,"latestPrice":0.475,"committee":0.857873,"eps":-0.045402,"divideRate":0,"volume":859452,"delay":0,"ttmEps":-0.045402,"open":0.47,"prevYearClose":0.3,"prevWeekClose":0.475,"prevMonthClose":0.49,"prevQuarterClose":0.3,"fiveDayClose":0.495,"twentyDayClose":0.54,"sixtyDayClose":0.412},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PAR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-02-06","symbol":"PAR.AU","defaultRemindTime":1738796400000,"type":"split","dateTimestamp":1738760400000,"forFactor":4,"toFactor":5,"ratio":0.8},{"market":"AU","date":"2022-08-17","symbol":"PAR.AU","defaultRemindTime":1660694400000,"type":"split","dateTimestamp":1660658400000,"forFactor":992772,"toFactor":1000000,"ratio":0.992772}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PAR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PAR.AU\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2490763750","title":"Paradigm Biopharmaceuticals Ltd -  Placement to Fund Global Phase 3 Clinical Trial Setup and Other Strategic Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2490763750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490763750?lang=en_us&edition=fundamental","pubTime":"2024-12-09 06:22","pubTimestamp":1733696544,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241208:nFWN3N800G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0},{"id":"2490075075","title":"Paradigm Biopharmaceuticals -  a$16M Placement at a$0.40 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2490075075","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490075075?lang=en_us&edition=fundamental","pubTime":"2024-12-09 06:22","pubTimestamp":1733696544,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241208:nFWN3N800G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0},{"id":"2489272653","title":"These small cap ASX shares could surge 27% to 38% higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2489272653","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489272653?lang=en_us&edition=fundamental","pubTime":"2024-12-08 06:22","pubTimestamp":1733610120,"startTime":"0","endTime":"0","summary":"Investors that have a high tolerance for risk might want to consider the small cap ASX shares in this article. That's because they have just been named as buys with major upside potential. Here's what","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/08/these-small-cap-asx-shares-could-surge-27-to-38-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7016","PAR.AU","PPS.AU","BK7508","BK7503","BK7064","PPS","BK7067","AIM.AU"],"gpt_icon":0},{"id":"2489812271","title":"This ASX healthcare stock is up 160% in a month! Here's why it's just entered a trading halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2489812271","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489812271?lang=en_us&edition=fundamental","pubTime":"2024-12-05 07:25","pubTimestamp":1733354745,"startTime":"0","endTime":"0","summary":"ASX healthcare stock Paradigm Biopharmaceuticals Ltd  has been on a strong run in the past month, soaring 160%.But the drug development company has requested a pause in the trading of its shares before the open on Thursday.Before the halt, Paradigm shares finished the session on Wednesday at 58 cents. Let's take a closer look.Paradigm requested its shares be put on ice starting Thursday, saying that it intends to update the market on a capital raising in the coming days.The pause in trading is expected to remain in place until next Monday, December 9, but trading will resume earlier if the ASX healthcare stock provides an update beforehand.Investors have flooded into Paradigm shares in recent weeks, with prices exploding on optimism surrounding its flagship drug candidate, Zilosul.Last week, the company confirmed it had not received feedback from the US Food and Drug Administration  regarding its revised Phase 3 clinical trial protocol for Zilosul.Meanwhile, Paradigm is also awaiting a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/05/this-asx-healthcare-stock-is-up-160-in-a-month-heres-why-its-just-entered-a-trading-halt/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["TGA","PAR.AU","TGA.AU","BK7067","BK4213","IND.AU","BK7508","BK7095","BK7001"],"gpt_icon":0},{"id":"2489535125","title":"BRIEF-Paradigm Biopharmaceuticals Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2489535125","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489535125?lang=en_us&edition=fundamental","pubTime":"2024-12-05 06:10","pubTimestamp":1733350259,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Seeks Trading HaltDec 5 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX:TRADING HALT PENDING CAPITAL RAISING ANNOUNCEMENTFurther company coverage: PAR.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nFWN3N51NI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAR.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2489128268","title":"Paradigm Biopharmaceuticals Ltd - Trading Halt Pending Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2489128268","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489128268?lang=en_us&edition=fundamental","pubTime":"2024-12-05 05:45","pubTimestamp":1733348738,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nFWN3N51NI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0},{"id":"2487581226","title":"PhosCo runs hard on Tunisian phosphate","url":"https://stock-news.laohu8.com/highlight/detail?id=2487581226","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487581226?lang=en_us&edition=fundamental","pubTime":"2024-11-29 07:18","pubTimestamp":1732835886,"startTime":"0","endTime":"0","summary":"This week’s Bulls N’ Bears Runner of the Week is … PhosCo. The African phosphate explorer nabbed a vital exploration permit, while Paradigm Biopharmaceuticals, AV Jennings and Errawarra Resources also ran hard.","market":"us","thumbnail":"https://images.thewest.com.au/publication/C-16921097/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-16921097/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/phosco-runs-hard-on-tunisian-phosphate--c-16921097","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/phosco-runs-hard-on-tunisian-phosphate--c-16921097","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["BK7095","BK7508","PAR.AU","PHO.AU","BK7067"],"gpt_icon":0},{"id":"2486967335","title":"Paradigm Biopharmaceuticals to Advance Knee Osteoarthritis Trial to Phase 3 Following US FDA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2486967335","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486967335?lang=en_us&edition=fundamental","pubTime":"2024-11-28 09:36","pubTimestamp":1732757813,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  will proceed with a phase 3 knee osteoarthritis trial of Zilosul, following a 30-day review by the US Food and Drug Administration of its clinical trial protocol, according to a Thursday filing with the Australian bourse.The study's primary endpoint is a change from baseline in pain using injectable pentosan polysulfate sodium, with changes in the Patient's Global Impression of Pain, functional assessments at specific time points, and structural changes as secondary endpoints, the filing said.Patient enrollment will start in the first quarter of next year at 10 Australian clinical trial sites, followed by US sites, as per the filing.The company's shares tumbled almost 14% in recent Thursday trade.Price : $0.50, Change: $-0.08, Percent Change: -13.91%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0994945656.USD","BK7508","LU2238339852.HKD","XKO.AU","LU0426417589.USD","XAO.AU","XJO.AU","LU0426412945.USD","BK7067","LU0345774631.USD","BK4125","PAR.AU","AUD","LU1043141123.HKD"],"gpt_icon":0},{"id":"2486736776","title":"Why did this ASX biotech stock explode 52% higher on Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2486736776","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486736776?lang=en_us&edition=fundamental","pubTime":"2024-11-25 14:21","pubTimestamp":1732515686,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals Ltd  shares started the week with an almighty bang. The ASX biotech stock ended the session almost 42% higher at 46 cents. At one stage, the biopharmaceutical company's shares were up as much as 52% to a 52-week high of 49.5 cents. Why did this ASX biotech stock rocket?Investors were bidding the company's shares higher today despite there being no news out of it. Though, interestingly, the lack of news was arguably the trigger for this rampant buying, with investors deeming no news to be very good news. The buying was so strong that it even led to the Australian stock exchange operator giving the ASX biotech stock a speeding ticket. It said:  Is PAR aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?In response, the biotech said:  No, the Company is not aware of any information concerning it that has not been announced to the market which, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/25/why-did-this-asx-biotech-stock-explode-52-higher-on-monday/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4213","BK7001","PAR.AU","XJO.AU","BK7067","BK7508","TGA","TGA.AU","XKO.AU","XAO.AU"],"gpt_icon":0},{"id":"2485215014","title":"Catalyst Watch: Robotaxi IPO, OPEC+, holiday shopping data, and movie blockbusters","url":"https://stock-news.laohu8.com/highlight/detail?id=2485215014","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485215014?lang=en_us&edition=fundamental","pubTime":"2024-11-23 04:00","pubTimestamp":1732305604,"startTime":"0","endTime":"0","summary":"blackdovfx/iStock via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock pri","market":"other","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1431931564/image_1431931564.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1431931564/image_1431931564.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4322051-catalyst-watch-robotaxi-ipo-opec-holiday-shopping-data-and-movie-blockbusters","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["US10Y.BOND","NTGR","JWN","DKS","QMmain","HPQ","CE","ETSY","SCO","MSTR.AU","PENN","ADI","PAR.AU","M","JNPR","DIS","A","IBRX","US7Y.BOND","AMZN","HEAR","FRO","TTGT","HNST","UCO","CLmain","BBY","SPY","US2Y.BOND","CMCSA","USO","SONO","ENVX","WDAY","ADI.AU","US5Y.BOND","BBWI","SJM","PAR","TRUE","VSTO","ZNOG","REGN","PARA","ZM","US30Y.BOND"],"gpt_icon":1},{"id":"2485498339","title":"PAR Technology to Exchange $100 Million Convertible Senior Notes Due 2026 for Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2485498339","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485498339?lang=en_us&edition=fundamental","pubTime":"2024-11-21 20:35","pubTimestamp":1732192503,"startTime":"0","endTime":"0","summary":"PAR Technology  said Thursday that it has signed private deals with certain holders to exchange $100 million total principal amount of its outstanding 2.875% convertible senior notes due 2026 for roughly 2.4 million of its common shares and about $336,000 in cash.The exchange is expected to be completed on Wednesday, the company said.Upon exchange, a total of $20 million principal amount of the notes will remain outstanding, PAR said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","PAR.AU","PAR","BK4157"],"gpt_icon":0},{"id":"2479729644","title":"ASX Market Close: Gold hits record high ahead of US election | October 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2479729644","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479729644?lang=en_us&edition=fundamental","pubTime":"2024-10-31 14:21","pubTimestamp":1730355660,"startTime":"0","endTime":"0","summary":"The ASX200 closed down 0.25% at 8,160 points.Gold climbed to a record high as investors engaged in a flight to safety. Demand for goal has soared in the week before the U.S. election and reached US$2790 per ounce.IT was the biggest gainer, up 0.52%, followed by Discretionary, up 0.17%.Staples finished the worst performing sector, down 1.65%, followed by Utilities, down 0.9%, and Materials, down 0.7%.Paradigm Pharmaceuticals  closed up 5% after the companyreported advancements in its Phase 3 clinical trial preparations for the treatment of knee osteoarthritis with its product.JB Hi-Fi  closed up 5.3% after releasing a sales update. The company reported total sales growth of 4.9% in Australia and 19.6% for New Zealand.Trek Metals  closed up 21.43% after intersecting broad zones of high-grade gold mineralisation in its maiden drilling program at the 100%-owned Christmas Creek Gold and Rare Earth Element Project in the Kimberley region of WA.Woolworths  closed down 2.76%, further extending","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-gold-hits-record-high-ahead-of-us-election-october-31-2024-2024-10-31/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["AGL.AU","TKM.AU","BK7511","WDS.AU","WOW.AU","PAR.AU","BK7067","JBH.AU","BK7508","BK7095","BK7142","BK7136","BK7040","BK7001","BK7501"],"gpt_icon":0},{"id":"2479523715","title":"2 All Ords ASX healthcare shares making BIG moves on quarterly updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2479523715","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479523715?lang=en_us&edition=fundamental","pubTime":"2024-10-31 09:39","pubTimestamp":1730338765,"startTime":"0","endTime":"0","summary":"Paradigm share price lifts off on trial progress The Paradigm Biopharmaceuticals Ltd  share price is up 2.5% at the time of writing, having earlier posted gains of 17.5%. Shares are currently changing hands for 20.5 cents apiece. That leaves the All Ords ASX healthcare share down 51% since this time last year. Investors have been bidding up the Paradigm share price after the company reported on the \"substantial progress\" it made over the quarter in its Phase 3 clinical trial preparations for the treatment of knee osteoarthritis with its iPPS product. Commenting on the recent achievements, Paradigm Biopharmaceuticals managing director Paul Rennie said, \"The submission of our phase 3 protocol to the FDA is a significant milestone for Paradigm.\" Rennie continued:  It represents the culmination of extensive work by our team and close collaboration with the FDA. We are confident that this progress, combined with the anticipated TGA [Therapeutic Goods Administration] response and our ongoing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/31/2-all-ords-asx-healthcare-shares-making-big-moves-on-quarterly-updates/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK4114","BK7508","BIG","XJO.AU","BK4220","IMU.AU","PAR.AU","XAO.AU"],"gpt_icon":0},{"id":"2468307301","title":"ASX Market Close: Index hits new intra-day high in flat days trade | September 18, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2468307301","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468307301?lang=en_us&edition=fundamental","pubTime":"2024-09-18 15:12","pubTimestamp":1726643520,"startTime":"0","endTime":"0","summary":"The ASX200 closed up 0.02% at 8,142 points in a flat days trade.Australian shares broke an intra-day record during a volatile day, as investors await the US Fed rate decision due tomorrow Australian time.The big iron ore miners pared early gains and tracked lower iron ore prices after a two-day holiday in China. It’s the first day of trading since China released underwhelming economic data last weekend and Iron ore futures fell 1.5 per cent to $US90.80 per barrel in Singapore.Utilities was the leading sector up 1.2%, followed by Energy, up 0.7%. The biggest losers today were Materials down 0.55% and Health Care, down 0.43%.88 Energy closed up 33% after revealing a “significant contingent resource update” for Project Phoenix. The estimate has been verified by ERCE Australia, a globally respected authority in petroleum reserve and resource auditing.Metalcity Ltd closed up more than 11% after sharing a 77-hole maiden drilling program at its Yundamindra gold project in Western Australia sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-index-hits-new-intra-day-high-in-flat-days-trade-september-18-2024-2024-09-18/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","ORG.AU","BK7130","BK7506","BK7006","BK7507","88E.AU","BK7511","PAR.AU","XAO.AU","BK7095","BHP.AU","AMI.AU","BK7508","XKO.AU","XJO.AU","BK7142"],"gpt_icon":0},{"id":"2468534362","title":"FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?","url":"https://stock-news.laohu8.com/highlight/detail?id=2468534362","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468534362?lang=en_us&edition=fundamental","pubTime":"2024-09-18 07:42","pubTimestamp":1726616520,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  has confirmed that it will use a twice weekly dosage of 2mg/kg injectable pentosan polysulfate sodium  in its looming Phase 3 knee osteoarthritis trial in the US.PAR lodged a ‘Type D meeting response‘ to the USA’s Food and Drug Administration  back in April of 2024; Wednesday’s news covers the agency’s response.Without saying it, Paradigm has ultimately highlighted the FDA has asked it to re-jig some specifics around its Phase 3 osteo trial for patients affected by complications in the knee. At least one HotCopper user classified the announcement as pointing to a “delay.”But Paradigm doesn’t see it that way – with much focus placed on the acceptance of the company’s proposed dosing regimen to be used in the Phase 3 trial – whenever that may be.“This is a significant outcome for Paradigm, since based on the clinical data generated to date, with a dosing regimen of 2mg/kg iPPS administered twice weekly, the phase 3 clinical trial is best set up for success,” ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/fda-hands-paradigm-biopharma-guidance-to-re-jig-phase-3-osteo-trial-or-is-it-a-delay-2024-09-18/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7503","PPS.AU","BK7508","BK7067","PAR.AU","BK7016","PPS"],"gpt_icon":0}],"pageSize":16,"totalPage":2,"pageCount":2,"totalSize":31}]}}